In the last trading session, 2.4 million Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) shares changed hands as the company’s beta touched 2.51. With the company’s per share price at $0.57 changed hands at $0.02 or 3.69% during last session, the market valuation stood at $146.52M. ADAP’s last price was a discount, traded about -259.65% off its 52-week high of $2.05. The share price had its 52-week low at $0.53, which suggests the last value was 7.02% up since then.
Analysts gave the Adaptimmune Therapeutics Plc ADR (ADAP) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.89. If we narrow down to specifics, the data shows that 1 out of 6 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended ADAP as a Hold, 4 felt it is a Buy and 0 rated the stock as Underweight. Adaptimmune Therapeutics Plc ADR’s EPS for the current quarter is expected to be -0.15.
Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) trade information
Instantly ADAP was in green as seen at the end of in last trading. With action -1.67%, the performance over the past five days has been red. The company’s shares are showing year-to-date upside of 6.29%, with the 5-day performance at -1.67% in the red. However, in the 30-day time frame, Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) is -3.26% down.
The consensus price target for the stock as assigned by Wall Street analysts is 3, meaning bulls need an upside of 81.0% from its current market value. According to analyst projections, ADAP’s forecast low is 1 with 4 as the target high. To hit the forecast high, the stock’s price needs a -601.75% plunge from its current level, while the stock would need to soar -75.44% for it to hit the projected low.
Adaptimmune Therapeutics Plc ADR (ADAP) estimates and forecasts
Year-over-year growth is forecast to reach 204.78% up from the last financial year.
Consensus estimates given by 9 financial analysts project the company’s revenue in the current quarter to hit an average of 8.77M. 3 analysts are of the opinion that Adaptimmune Therapeutics Plc ADR’s revenue for the current quarter will be 6.3M. The company’s revenue for the corresponding quarters a year ago was 231k and 5.68M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 3,697.50%. The estimates for the next quarter sales put growth at 10.95%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 10.30%. The 2025 estimates are for Adaptimmune Therapeutics Plc ADR earnings to increase by 71.06%.
ADAP Dividends
Adaptimmune Therapeutics Plc ADR is expected to release its next quarterly earnings report in March.
BANK OF AMERICA CORP /DE/ holds the second largest percentage of outstanding shares, with 1.9239% or 4.65 million shares worth $4.53 million as of 2024-06-30.
Among Mutual Funds, the top two as of Nov 30, 2024 were SPDR Portfolio Developed World ex-US ETF and SEI Institutional International Tr-International Equity . With 251.08 shares estimated at $0.14 million under it, the former controlled 0.10% of total outstanding shares. On the other hand, SEI Institutional International Tr-International Equity held about 0.07% of the shares, roughly 175.24 shares worth around $0.1 million.
